More threads by Retired


Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO? (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States
September 19, 2017

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Nuvelution Pharma, Inc. today announced their partnership to develop AUSTEDO? (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome (TS) in pediatric patients in the United States. This partnership will accelerate development of Austedo? in TS, hopefully bringing a much needed new treatment option to affected young patients more quickly.

AUSTEDO? is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington?s disease.

Complete article

Related articles:

Globes English - Teva teams with Nuvelution on Tourette syndrome drug


Attached is PDF :acrobat: of U.S. Full Prescribing Information, including Boxed Warning


  • PrescribingInformation.pdf
    911.2 KB · Views: 0
Replying is not possible. This forum is only available as an archive.